Aurora Spine Corp's Q3 revenue down 7.1%

Aurora Spine

18/11/2025 12:23

Overview

Aurora Spine Q3 2025 revenue down 7.1% yr/yr due to transition in lumbar products

Company reports positive EBITDAC for second consecutive quarter despite lower revenue

Aurora Spine launched DEXA-L and Hydra ARO products, achieving initial sales in Q3 2025

Outlook

Company aims to expand sales team and educate surgeons about new products

Aurora Spine sees new product launches as growth catalysts for future

Company is sufficiently capitalized to pursue growth opportunities

Result Drivers

PRODUCT LAUNCHES - Introduction of DEXA-L and Hydra ARO contributed to initial sales in Q3 2025

LUMBAR PRODUCT TRANSITION - Shift from third-party lumbar screws to Osteo Onyx lumbar product impacted sales

POSITIVE EBITDAC - Company maintained positive EBITDAC despite lower revenue levels

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Operating Expenses
$2.81 mln


Analyst Coverage

The stock recently traded at 2 times the next 12-month earnings vs. a P/E of 2 three months ago

Press Release: ID:nGNX1YxfNB

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)